$BLRX News

BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026

BioLineRx And Hemispherian Present Data At ESMO 2026 Demonstrating Synergy Between GLIX1 And Multiple PARPi In Homologous Recombination-Proficient Ovarian Cancer Cell Lines And In In Vivo Patient-Derived Xenograft Model

BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day

BioLineRx Announces That Two Abstracts Featuring GLIX1 Will Be Presented At The Society For Neuro-Oncology Annual Meeting, November 12-15

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

BioLineRx And Hemispherian To Present Preclinical Efficacy Of GLIX1 In Orthotopic Glioblastoma Models, At 21st Meeting Of EANO 2026

BLRX: New GLIX1 Data Touts Synergies

BioLine Rx Ltd (BLRX) (Q2 2026) Earnings Call Highlights: Advancing GLIX1 Pipeline and ...

BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BioLine Rx Q2 Sales $294.000K Miss $500.000K Estimate

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

BioLineRx Announces $3.75M Registered Direct Offering Of ADSs At $2.78 Each And Concurrent Private Placement Of Warrants For Up To 2M ADSs

BioLineRx to Report Second Quarter 2026 Results on August 31, 2026

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026

BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In October

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

BioLineRx And Hemispherian Announce New Preclinical Data Showing Strong Synergy Between GLIX1 And PARP Inhibitors In Patient-Derived Xenograft Model Of Ovarian Cancer

BioLine Rx Ltd (BLRX) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update